Matches in SemOpenAlex for { <https://semopenalex.org/work/W2520258587> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2520258587 endingPage "e114" @default.
- W2520258587 startingPage "e114" @default.
- W2520258587 abstract "Objective: Recently elevated level of antibodies against NMDA subunit NR2 had been described as biomarker for acute cerebrovascular lesion. Arterial hypertension is powerful modifiable vascular risk factor for stroke initiation and recurrence. We aimed to determine whether serum NR2-antibodies level associated with risk of recurrent stroke in hypertensive patients. Design and Method: High-risk hypertensive patients (n = 120) who had ischemic stroke in anamnesis were prospectively enrolled for this study. Serum concentrations of NR2-antibodies had been tested at baseline in all patients and 30 normotensive subjects (control group). Brain MRIs were assessed in all post-stroke hypertensives initially. Mean follow-up duration was 2.5 ± 1.7 years. Multivariable Cox-regression models were applied to identify risk factors for stroke recurrence. Results: Of 120 subjects enrolled, recurrent ischemic stroke occurred in 14 (11.7%) patients. Baseline mean NR2 peptide antibodies level was 3.3 ± 1.5 ng/mL in high-risk hypertensives compared with 1.45 ± 0.7 ng/mL in control group (p < 0.001). Median NR2 peptide antibodies level was significantly higher in those patients who sustained an recurrent stroke compared with those who did not (4.2 ± 1.2 ng/mL versus 2.7 ± 1.8 ng/mL, p = 0.003). According to weighted Cox proportional hazard model after adjustment for age, sex, ethnic group the risk of recurrent ischemic stroke at follow-up had increased in hypertensives with baseline NR2 peptide antibodies level ≥ 4.5 ng/mL (HR 1.25; 95% CI, 1.06–1.37) as well as in patients with elevated NR2 antibodies level combined with multifocal brain lesion (HR 4.36; 95% CI, 1.6–12.2) and abnormal circadian blood pressure profile (HR 3.13; 95% CI, 1.1–12.7 respectively). Conclusions: Serum level of NR2 peptide antibodies may represent a novel biomarker of ischemic stroke recurrence in high risk hypertensive patients." @default.
- W2520258587 created "2016-09-23" @default.
- W2520258587 creator A5024046595 @default.
- W2520258587 creator A5053290794 @default.
- W2520258587 creator A5079443687 @default.
- W2520258587 creator A5085179220 @default.
- W2520258587 date "2016-09-01" @default.
- W2520258587 modified "2023-09-25" @default.
- W2520258587 title "PS 02-37 SERUM NR2 PEPTIDE ANTIBODIES AND STROKE RECURRENCE IN HIGH-RISK HYPERTENSIVES" @default.
- W2520258587 doi "https://doi.org/10.1097/01.hjh.0000500164.46902.a3" @default.
- W2520258587 hasPublicationYear "2016" @default.
- W2520258587 type Work @default.
- W2520258587 sameAs 2520258587 @default.
- W2520258587 citedByCount "0" @default.
- W2520258587 crossrefType "journal-article" @default.
- W2520258587 hasAuthorship W2520258587A5024046595 @default.
- W2520258587 hasAuthorship W2520258587A5053290794 @default.
- W2520258587 hasAuthorship W2520258587A5079443687 @default.
- W2520258587 hasAuthorship W2520258587A5085179220 @default.
- W2520258587 hasConcept C126322002 @default.
- W2520258587 hasConcept C127413603 @default.
- W2520258587 hasConcept C141071460 @default.
- W2520258587 hasConcept C159654299 @default.
- W2520258587 hasConcept C164705383 @default.
- W2520258587 hasConcept C185592680 @default.
- W2520258587 hasConcept C203014093 @default.
- W2520258587 hasConcept C207103383 @default.
- W2520258587 hasConcept C2780645631 @default.
- W2520258587 hasConcept C2781197716 @default.
- W2520258587 hasConcept C44249647 @default.
- W2520258587 hasConcept C50382708 @default.
- W2520258587 hasConcept C50440223 @default.
- W2520258587 hasConcept C55493867 @default.
- W2520258587 hasConcept C71924100 @default.
- W2520258587 hasConcept C78519656 @default.
- W2520258587 hasConcept C90924648 @default.
- W2520258587 hasConceptScore W2520258587C126322002 @default.
- W2520258587 hasConceptScore W2520258587C127413603 @default.
- W2520258587 hasConceptScore W2520258587C141071460 @default.
- W2520258587 hasConceptScore W2520258587C159654299 @default.
- W2520258587 hasConceptScore W2520258587C164705383 @default.
- W2520258587 hasConceptScore W2520258587C185592680 @default.
- W2520258587 hasConceptScore W2520258587C203014093 @default.
- W2520258587 hasConceptScore W2520258587C207103383 @default.
- W2520258587 hasConceptScore W2520258587C2780645631 @default.
- W2520258587 hasConceptScore W2520258587C2781197716 @default.
- W2520258587 hasConceptScore W2520258587C44249647 @default.
- W2520258587 hasConceptScore W2520258587C50382708 @default.
- W2520258587 hasConceptScore W2520258587C50440223 @default.
- W2520258587 hasConceptScore W2520258587C55493867 @default.
- W2520258587 hasConceptScore W2520258587C71924100 @default.
- W2520258587 hasConceptScore W2520258587C78519656 @default.
- W2520258587 hasConceptScore W2520258587C90924648 @default.
- W2520258587 hasIssue "Supplement 1" @default.
- W2520258587 hasLocation W25202585871 @default.
- W2520258587 hasOpenAccess W2520258587 @default.
- W2520258587 hasPrimaryLocation W25202585871 @default.
- W2520258587 hasRelatedWork W2996455937 @default.
- W2520258587 hasRelatedWork W3049631826 @default.
- W2520258587 hasRelatedWork W3134297040 @default.
- W2520258587 hasRelatedWork W3146893803 @default.
- W2520258587 hasRelatedWork W4206297930 @default.
- W2520258587 hasRelatedWork W4206396577 @default.
- W2520258587 hasRelatedWork W4226144840 @default.
- W2520258587 hasRelatedWork W4229009061 @default.
- W2520258587 hasRelatedWork W4309151816 @default.
- W2520258587 hasRelatedWork W4366351077 @default.
- W2520258587 hasVolume "34" @default.
- W2520258587 isParatext "false" @default.
- W2520258587 isRetracted "false" @default.
- W2520258587 magId "2520258587" @default.
- W2520258587 workType "article" @default.